Business, energy, technology, markets and global industry news from Business News Today

precision oncology

PharmaDeviceNews precision oncology
Representative image: GSK’s $10.6 billion Nuvalent deal puts precision lung cancer therapies in focus as Big Pharma races to secure late-stage oncology assets.
Pharma & Biotech

Why GSK is paying $10.6bn for Nuvalent as targeted lung cancer drugs near FDA decisions

GSK is betting $10.6B on Nuvalent’s lung cancer drugs. The payoff now depends on FDA decisions, labels and oncology launch execution.

Read More
Representative image of clinicians reviewing AI-enabled radiation therapy planning scans, illustrating how GE HealthCare’s MIM Contour ProtégéAI+ 2.0 FDA clearance could speed precision cancer treatment workflows.
Medical Devices & Diagnostics

GE HealthCare’s MIM Contour ProtégéAI+ clearance raises the stakes in radiotherapy automation

GE HealthCare’s MIM Contour ProtégéAI+ 2.0 clearance could speed radiation therapy planning. Find out what changes next.

Read More
Representative image of an AI-enabled precision oncology research meeting, illustrating how SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center could turn cancer data into a precision medicine engine.
Medical Devices & Diagnostics

Can SOPHiA GENETICS and Memorial Sloan Kettering turn oncology data into a precision medicine engine?

SOPHiA GENETICS and Memorial Sloan Kettering aim to turn cancer data into precision oncology infrastructure. Can the hub deliver?

Read More
Representative image of clinicians reviewing genomic cancer testing data and medical imaging, reflecting Veracyte’s Prosigna and Decipher ASCO 2026 results and the growing role of precision oncology diagnostics in breast cancer and prostate cancer treatment decisions.
Medical Devices & Diagnostics

Can Veracyte’s Prosigna data change chemotherapy decisions in high-risk breast cancer?

Veracyte’s ASCO data could reshape chemotherapy decisions in breast and prostate cancer. Find out why genomic testing is gaining ground.

Read More
Representative image of an oncologist reviewing lung cancer scans with a patient, reflecting Nuvalent’s neladalkib FDA Priority Review and the growing race to develop targeted therapies for ALK-positive non-small cell lung cancer.
Pharma & Biotech

Nuvalent’s ALK inhibitor gets Priority Review as lung cancer treatment sequencing evolves

Nuvalent’s neladalkib has FDA Priority Review in ALK-positive lung cancer. Find out why resistance and brain metastases drive the story.

Read More
Representative image of oncology researchers reviewing cancer scans and molecular data, reflecting Ranok Therapeutics’ RNK08954 Phase 1a results and the accelerating race to develop KRAS G12D targeted therapies for pancreatic cancer, lung cancer and other advanced solid tumours.
Pharma & Biotech

Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up

KRAS G12D was long seen as nearly untouchable. Ranok’s RNK08954 now has early clinical data, but the pivotal test is still ahead.

Read More
Representative image of an oncology researcher reviewing colorectal cancer scan data, reflecting Pfizer’s Braftovi regimen update in BRAF V600E-mutant metastatic colorectal cancer.
Pharma & Biotech

Is Pfizer’s Braftovi regimen becoming the new benchmark for BRAF-mutant colorectal cancer?

Pfizer’s Braftovi data strengthen its role in BRAF V600E metastatic colorectal cancer. Find out what this could change next.

Read More
Representative image of an oncologist and clinical care team reviewing AI-powered cancer trial data, reflecting Massive Bio’s Reticulum Nexus push to improve oncology trial matching, biomarker reassessment and patient access after its ASCO 2026 product suite announcement.
Pharma & Biotech

How Massive Bio’s Reticulum Nexus suite is targeting the hidden bottlenecks in cancer trials

Can Massive Bio’s Reticulum Nexus suite close oncology trial access gaps? Find out how AI agents may reshape cancer trial navigation today!

Read More
Representative image of oncology researchers reviewing lung cancer imaging and genomic data, reflecting Kelun-Biotech’s lunbotinib fumarate Phase II results in RET fusion-positive non-small cell lung cancer.
Pharma & Biotech

Kelun-Biotech’s ASCO 2026 data strengthens China’s next wave of targeted cancer drugs

Kelun-Biotech’s RET lung cancer data looks strong, but CNS durability and global competition will decide its real impact.

Read More
Representative image of radioligand therapy research for cancer-associated bone disease, highlighting how LIFT and NorthStar’s Lu-177-LT17 collaboration could advance targeted oncology treatment for bone lesions.
Pharma & Biotech

Can LIFT and NorthStar move Lu-177-LT17 into the next radioligand therapy frontier?

Find out how LIFT and NorthStar’s Lu-177-LT17 partnership could advance radioligand therapy for cancer bone disease today!

Read More